1/164
Looks like no tags are added yet.
2.1 | Corpus callosum
Connects the two cerebral hemispheres and allows them to communicate.
2.1 | Cerebellum
Coordinates balance, posture, and movement.
2.1 | Thalamus
Major relay station that sends sensory information to the cerebral cortex.
2.1 | Hypothalamus
Regulates endocrine and autonomic/visceral functions, temperature, hunger, and homeostasis.
2.1 | Limbic system
Involved in emotion and memory.
2.1 | Frontal lobe
Important for planning, judgment, decision-making, and voluntary movement.
2.1 | Reception
Detection of a stimulus by a sensory receptor.
2.1 | Transduction
Conversion of a stimulus into an electrical signal or generator potential.
2.1 | Coding
Encoding stimulus information, such as intensity, through neuronal firing patterns/frequency.
2.1 | At what stage does perception occur?
At the coding/central processing stage, not at transduction.
2.2 | A-delta fibers
Fast, sharp, well-localized pain; thinly myelinated.
2.2 | C fibers
Slow, dull, burning pain; unmyelinated.
2.2 | A-beta fibers
Primarily carry non-painful touch/pressure information.
2.2 | Bradykinin
Inflammatory mediator that contributes strongly to pain and vasodilation.
2.2 | Histamine
Promotes vasodilation and especially increases vascular permeability in acute inflammation.
2.2 | Prostaglandins
Contribute to inflammation, vasodilation, and pain sensitization.
2.2 | Leukotrienes
Inflammatory mediators; promote bronchoconstriction and are important in asthma/allergic inflammation.
2.2 | TNF-alpha
Pro-inflammatory cytokine involved in chronic inflammation, including rheumatoid arthritis.
2.2 | Paresthesia
Abnormal sensation such as tingling, prickling, or pins and needles.
2.2 | Dysesthesia
Unpleasant abnormal sensation, often burning or painful.
2.2 | Hyperalgesia
Increased pain response to a stimulus that is normally painful.
2.2 | Allodynia
Pain caused by a stimulus that is normally not painful.
2.2 | Causalgia
Persistent burning pain, typically associated with nerve injury/complex regional pain syndrome.
2.2 | Phantom limb pain
Pain perceived in a limb or body part that has been amputated.
2.2 | Anesthesia dolorosa
Pain in an area that is otherwise numb, often after nerve injury.
2.2 | Diabetic peripheral neuropathy
Nerve damage from diabetes that can cause numbness, tingling, burning pain, or altered sensation, often in the feet.
2.2 | NSAIDs
Best suited for pain associated with inflammation and tissue injury.
2.2 | Opioids
Act on opioid receptors to reduce pain signaling; used for moderate-to-severe pain but carry respiratory-depression and dependence risks.
2.2 | Gabapentin and other anticonvulsants
Commonly used for neuropathic pain.
2.2 | TCAs (e.g., amitriptyline)
Can treat neuropathic pain by altering monoamine signaling.
2.2 | Local anesthetics
Block voltage-gated sodium channels to prevent action-potential conduction and sensation.
2.3 | NMDA receptor
Ionotropic glutamate receptor permeable to Na+ and Ca2+ (with K+ efflux); blocked by Mg2+ at resting membrane potential.
2.3 | What removes the Mg2+ block from NMDA?
Postsynaptic depolarization, typically produced by glutamate-driven AMPA receptor activity.
2.3 | Long-term potentiation (LTP)
Long-lasting strengthening of synaptic transmission; classically involves glutamate, NMDA receptor activation, and removal of the Mg2+ block.
2.3 | Glutaminase
Converts glutamine into glutamate.
2.3 | Glutamine synthetase
Converts glutamate into glutamine, mainly in glial cells.
2.3 | Glutamate dehydrogenase (GDH)
Converts glutamate into alpha-ketoglutarate.
2.3 | EAAT
Excitatory amino acid transporter; mediates glutamate reuptake into neurons and glial cells.
2.3 | VGLUT
Vesicular glutamate transporter; packages glutamate into synaptic vesicles.
2.4 | GABA synthesis
Glutamate is converted to GABA by glutamic acid decarboxylase (GAD).
2.4 | GAT
GABA transporter responsible for GABA reuptake into neurons and glial cells.
2.4 | VGAT
Vesicular GABA transporter; also transports glycine into vesicles.
2.4 | GABA-T
Enzyme that metabolizes GABA to glutamate-related intermediates, especially in glial cells.
2.4 | GABAA receptor
Ionotropic Cl− channel; produces fast inhibitory signaling, generally hyperpolarizing the postsynaptic neuron.
2.4 | GABAB receptor
Metabotropic Gi/o-coupled receptor; inhibits adenylyl cyclase, reduces Ca2+ entry, and increases K+ conductance to inhibit neurotransmitter release.
2.4 | Benzodiazepines
Positive allosteric modulators of GABAA receptors; increase the effect of GABA and promote anxiolysis/sedation.
2.4 | Baclofen
GABAB receptor agonist.
2.4 | Muscimol
GABAA receptor agonist.
2.5 | Dopamine synthesis
Tyrosine → L-DOPA via tyrosine hydroxylase → dopamine via DOPA decarboxylase/AADC.
2.5 | Rate-limiting enzyme in dopamine synthesis
Tyrosine hydroxylase.
2.5 | DAT
Dopamine transporter; reuptakes dopamine from the synapse into the presynaptic neuron.
2.5 | VMAT1/2
Vesicular monoamine transporters; package dopamine and other monoamines into vesicles.
2.5 | Dopamine metabolism
Primarily by MAO and COMT; metabolites include DOPAC and homovanillic acid (HVA).
2.5 | D1 receptors
Generally excitatory; coupled to Gs and increase cAMP.
2.5 | D2 receptors
Generally inhibitory; coupled to Gi and decrease cAMP.
2.5 | Apomorphine
D2 agonist; D2 activation in the chemoreceptor trigger zone can promote vomiting.
2.5 | Cocaine mechanism
Blocks DAT, reducing dopamine reuptake and increasing/prolonging dopamine in the synaptic space.
2.5 | A10 pathway
Mesolimbic dopamine pathway strongly associated with reward, reinforcement, and addiction.
2.6 | Norepinephrine synthesis
Dopamine is converted to norepinephrine by dopamine beta-hydroxylase.
2.6 | Epinephrine synthesis
Norepinephrine is converted to epinephrine by phenylethanolamine N-methyltransferase (PNMT).
2.6 | NE/EPI reuptake
Primarily by NET.
2.6 | NE/EPI vesicular transport
VMAT packages norepinephrine and epinephrine into vesicles.
2.6 | NE/EPI metabolism
MAO and COMT.
2.6 | NE in locus coeruleus
Supports arousal/alertness, attention, and memory-related functions.
2.6 | MAOI food interaction
MAOIs reduce tyramine breakdown; high tyramine intake can cause excessive catecholamine release and hypertensive crisis.
2.6 | Propranolol
Nonselective beta-adrenergic antagonist; blocks beta receptor signaling and reduces heart rate and blood pressure.
2.7 | Acetylcholine synthesis
Choline + acetyl-CoA are combined by choline acetyltransferase (ChAT) to form ACh.
2.7 | CHT1
High-affinity choline transporter that brings choline into the presynaptic neuron.
2.7 | VAChT
Vesicular acetylcholine transporter; packages ACh into synaptic vesicles.
2.7 | Does acetylcholine undergo reuptake?
NO. Acetylcholine is broken down in the synaptic cleft by acetylcholinesterase; choline is taken back up by CHT1 and reused.
2.7 | Acetylcholinesterase (AChE)
Breaks acetylcholine into choline and acetate in the synaptic cleft.
2.7 | nAChR
Nicotinic acetylcholine receptor; ionotropic, ligand-gated cation channel that produces fast excitation.
2.7 | mAChR
Muscarinic acetylcholine receptor; metabotropic GPCR with slower effects that can be excitatory or inhibitory depending on subtype.
2.7 | M1/M3/M5 receptors
Muscarinic receptor subtypes generally coupled to Gq and excitatory signaling.
2.7 | M2/M4 receptors
Muscarinic receptor subtypes generally coupled to Gi and inhibitory signaling.
2.7 | ACh in basal forebrain
Supports attention, learning, and information processing.
2.7 | ACh in brainstem (PPN/LDT)
Involved in sleep-wake regulation and motor control.
2.8 | Histamine synthesis
Histidine is converted to histamine by histidine decarboxylase.
2.8 | Histamine vesicular transport
VMAT packages histamine into vesicles in neurons.
2.8 | Does histamine undergo reuptake?
No; histamine signaling is primarily terminated by enzymatic metabolism.
2.8 | H1 receptor
Gq-coupled; associated with arousal and many allergic/inflammatory effects.
2.8 | H2 receptor
Gs-coupled; increases gastric acid secretion.
2.8 | H3 receptor
Gi/o-coupled presynaptic autoreceptor; reduces histamine release.
2.8 | H4 receptor
Gi/o-coupled; involved in immune and inflammatory responses.
2.8 | Pitolisant
H3 receptor antagonist/inverse agonist; increases histamine signaling and promotes wakefulness in narcolepsy.
2.8 | Why can H1 antihistamines cause drowsiness?
Blocking central H1 receptors reduces histamine-mediated arousal.
2.9 | Serotonin synthesis
Tryptophan → 5-HTP via tryptophan hydroxylase → serotonin via AADC.
2.9 | Rate-limiting enzyme in serotonin synthesis
Tryptophan hydroxylase.
2.9 | SERT
Serotonin transporter; reuptakes serotonin from the synapse.
2.9 | Fluoxetine
SSRI that inhibits SERT, reducing serotonin reuptake.
2.9 | Reserpine
Inhibits VMAT2, preventing monoamines such as serotonin from being packaged into vesicles.
2.9 | Serotonin metabolism
MAO followed by aldehyde dehydrogenase (ALDH) produces 5-HIAA.
2.9 | 5-HT1 autoreceptors
Presynaptic inhibitory Gi-coupled receptors that provide negative feedback and reduce serotonin firing/release.
2.9 | Does peripheral serotonin replenish brain serotonin?
No. Peripheral serotonin does not meaningfully cross the blood-brain barrier; the CNS synthesizes its own serotonin from tryptophan.
2.10 | Endorphins and opioid receptors
Endorphins preferentially bind mu (μ/MOR) receptors.
2.10 | Enkephalins and opioid receptors
Enkephalins preferentially bind delta (δ/DOR) receptors.
2.10 | Dynorphins and opioid receptors
Dynorphins preferentially bind kappa (κ/KOR) receptors.
2.10 | Opioid receptor signaling
MOR, DOR, and KOR are Gi/o-coupled GPCRs; inhibit adenylyl cyclase, decrease cAMP, increase K+ efflux, and decrease Ca2+ influx.
2.10 | How do opioids hyperpolarize neurons?
They increase K+ conductance/efflux, making the inside of the neuron more negative.
2.10 | How do opioids reduce neurotransmitter release?
They inhibit voltage-gated Ca2+ entry at presynaptic terminals.